Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
FeaturedThe Delhi High Court's ruling in Array Biopharma Inc. v. Deputy Controller clarifies that patent objections must be substantiated by evidence linked to the claims, highlighting judicial scrutiny in patent examination.
FeaturedThe Delhi High Court's judgment in Hindware Ltd. v. Grohe India Pvt. Ltd. underscores the issues of keyword advertising related to trademark infringement. This landmark ruling clarifies using registered trademarks as keywords in online advertising.
FeaturedThe Delhi High Court in Intra Cellular Therapies v. Controller of Patents tackles critical issues of disclosure and efficacy in the context of pharmaceutical patent law.
FeaturedThe Delhi High Court ruled in Array Biopharma Inc. v. Deputy Controller of Patents that patent objections must be substantiated by claims and evidence, rather than merely cited. This ruling emphasizes the necessity for a more rigorous application of the inventive step and relevance to Sections 3(d) and 3(i).
FeaturedThe Delhi High Court addressed two key issues in pharmaceutical patent law concerning disclosure and therapeutic efficacy in Intra Cellular Therapies v. Controller of Patents, highlighting ongoing complexities in patentability standards.
FeaturedIn Ashit Padhaya v. Assistant Controller of Patents and Designs, the Bombay High Court clarified that a Controller's reliance on undisclosed evidence undermines the post-grant opposition process. This ruling emphasizes the necessity of transparency in patent assessments for the protection of patentees.
FeaturedThe Delhi High Court's ruling in Intra Cellular Therapies v. Controller of Patents revisited critical issues regarding disclosure in pharmaceutical patents, specifically addressing the therapeutic efficacy threshold under Section 3(d) of the Patents Act.
FeaturedIn Intra Cellular Therapies v. Controller of Patents, the Delhi High Court revisits key elements of pharmaceutical patent law, focusing on disclosure and efficacy standards.
FeaturedThe Delhi High Court's ruling in Intra Cellular Therapies v. Controller of Patents examines key issues in pharmaceutical patent law, including disclosure standards and the efficacy threshold under Section 3(d). The decision influences future patent applications significantly.
FeaturedThe Delhi High Court has examined significant issues in pharmaceutical patent law regarding coverage disclosure and therapeutic efficacy thresholds in the Intra Cellular Therapies v. Controller of Patents case. This ruling underscores ongoing complexities in patent litigation.
FeaturedIn a significant ruling, the Delhi High Court addressed key issues in pharmaceutical patent law, particularly concerning coverage disclosure and therapeutic efficacy under Section 3(d) in the Intra Cellular Therapies v. Controller of Patents case.
FeaturedThe Delhi High Court has issued a ruling on dynamic injunctions in the HBO v. Streamzy case, exploring the balance between combating online piracy and safeguarding the roles of ISPs in the digital ecosystem.